1. Chang K, Chiu J-J. Clinical applications of nanotechnology in atherosclerotic diseases. Curr Nanosci. 2005;1(2):107-115.
2. Tcheng JE, O'Shea JC. Eptifibatide: a potent inhibitor of the platelet receptor integrin, glycoprotein IIb/IIIa.
Expert Opin Investig Drugs. 1999;
8(11):1893-1905.
pmid: 11139832
3. Addeo R, Faiola V, Guarrasi R, Montella L, Vincenzi B, Capasso E, et al. Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women > or = 65 years of age.
Cancer Chemother Pharmacol. 2008;
62(2):285-292.
doi: 10.1007/s00280-007-0605-6 pmid: 17922275
4. Torchilin VP. Targeting of drugs and drug carriers within the cardiovascular system Adv Drug Delivery Rev. 1995;17 75-101.
5. Mohammadian M, Farzampanah L, Behtash-oskouie A, Majdi S, Mohseni G, Imandar M, et al. A biosensor for detect nitrite (NO2-) and hydroxylamine (nh2oh) by using of hydroxylamine oxidase and modified electrode with ZnO nanoparticles. Int J Electrochem Sci. 2013;8(9):11215-11227.
7. Haller C. A., Cui W, Wen J, Robson SC, Chaikof E. L. Reconstitution of CD39 in liposomes amplifies nucleoside triphosphate diphosphohydrolase activity and restores thromboregulatory properties.
J Vasc Surg. 2006;
43(4):816-823.
doi: 10.1016/j.jvs.2005.11.057 pmid: 16616242
13. Srinivasan R, Marchant RE, Gupta AS. In vitro and in vivo platelet targeting by cyclic RGD-modified liposomes.
J Biomed Mater Res A. 2010;
93(3):1004-1015.
doi: 10.1002/jbm.a.32549 pmid: 19743511
14. Huang G, Zhou Z, Srinivasan R, Penn MS, Kottke-Marchant K, Marchant RE, et al. Affinity manipulation of surface-conjugated RGD peptide to modulate binding of liposomes to activated platelets.
Biomaterials. 2008;
29(11):1676-1685.
doi: 10.1016/j.biomaterial s.2007.12.015 pmid: 18192005
15. Mousavizadeh A, Jabbari A, Akrami M, Bardania HJC, Biointerfaces SB. Cell targeting peptides as smart ligands for targeting of therapeutic or diagnostic agents: A systematic review. Biointerfaces. 2017;158:507-517.
16. Vaidya B, Nayak MK, Dash D, Agrawal GP, Vyas SP. Development and characterization of site specific target sensitive liposomes for the delivery of thrombolytic agents.
Int J Pharm. 2011;
403(1-2):254-261.
doi: 10.1016/j.ijpharm.2010.10.028 pmid: 20971175
17. Lestini BJ, Sagnella SM, Xu Z, Shive MS, Richter NJ, Jayaseharan J, et al. Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery.
J Control Release. 2002;
78(1-3):235-247.
pmid: 11772464
19. Bardania H, Shojaosadati SA, Kobarfard F, Dorkoosh F. Optimization of RGD-modified Nano-liposomes Encapsulating Eptifibatide.
Iran J Biotechnol. 2016;
14(2):33-40.
doi: 10.15171/ijb.1399 pmid: 28959324
20. Bardania H, Shojaosadati SA, Kobarfard F, Dorkoosh F, Zadeh ME, Naraki M, et al. Encapsulation of eptifibatide in RGD-modified nanoliposomes improves platelet aggregation inhibitory activity.
J Thromb Thrombolysis. 2017;
43(2):184-193.
doi: 10.1007/s11239-016-1440-6 pmid: 27778144
21. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.
J Immunol Methods. 1983;
65(1-2):55-63.
pmid: 6606682
22. Krejsa CM, Schieven GL. Detection of oxidative stress in lymphocytes using dichlorodihydrofluorescein diacetate. Stress Response: Springer; 2000. p. 35-47.
23. Mohammad-Beigi H, Shojaosadati SA, Morshedi D, Arpanaei A, Marvian AT. Preparation and in vitro characterization of gallic acid-loaded human serum albumin nanoparticles. J Nanopart Res. 2015;17(4):1-16.
24. Kuznetsova NR, Sevrin C, Lespineux D, Bovin NV, Vodovozova EL, Meszaros T, et al. Hemocompatibility of liposomes loaded with lipophilic prodrugs of methotrexate and melphalan in the lipid bilayer.
J Control Release. 2012;
160(2):394-400.
doi: 10.1016/j.jconrel.2011.12.010 pmid: 22210161
25. Bender EA, Adorne MD, Colome LM, Abdalla DSP, Guterres SS, Pohlmann AR. Hemocompatibility of poly(varepsilon-caprolactone) lipid-core nanocapsules stabilized with polysorbate 80-lecithin and uncoated or coated with chitosan.
Int J Pharm. 2012;
426(1-2):271-279.
doi: 10.1016/j.ijpharm.2012.01.051 pmid: 22322210
27. Dokka S, Toledo D, Shi X, Castranova V, Rojanasakul Y. Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes.
Pharm Res. 2000;
17(5):521-525.
pmid: 10888302
28. Filion MC, Phillips NC. Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells.
Biochim Biophys Acta. 1997;
1329(2):345-356.
pmid: 9371426
30. Cadenas E, Davies KJ. Mitochondrial free radical generation, oxidative stress, and aging.
Free Radic Biol Med. 2000;
29(3-4):222-230.
pmid: 11035250